CLINICAL_TRIALS
trial_result
· 2012-11-26
Clinical Trial Update: Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes [Phase 2]
Summary
Phase 2 safety and tolerability update of AZD1656 in patients with type 2 diabetes after four weeks of treatment.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: AstraZeneca | Conditions: Type II Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2012-11-26